OZ BIOSCIENCES SAS

Their core work

OZ Biosciences is a Marseille-based biotech SME specializing in delivery technologies for biological molecules — particularly transfection reagents, gene delivery vectors, and biomaterial formulations. Within EU projects, they contribute expertise in formulating and delivering therapeutic agents (RNA, genes, bioactive compounds) into cells and tissues. Their applied work focuses on regenerative medicine, specifically bone repair using 3D-printed matrices loaded with gene therapy vectors and bioactive agents. They serve as a specialist supplier and development partner for consortia that need reliable intracellular delivery solutions.

What they specialise in

How they've shifted over time

In their early H2020 involvement (2016–2017), OZ Biosciences participated in broad training networks — NANOMED in nanomedicine and OcuTher in ocular therapeutics — suggesting a phase of capability building and network expansion across multiple delivery domains. By 2020, their focus sharpened dramatically toward bone regeneration using 3D-printed therapeutic matrices (cmRNAbone and SBR), combining their core delivery technology with advanced manufacturing and regenerative medicine. This pivot from general delivery science to a specific clinical application area — bone repair — signals a maturing company narrowing toward commercial translation.

OZ Biosciences is moving from broad delivery technology expertise toward specialized therapeutic applications in bone regeneration, positioning themselves at the intersection of gene therapy and 3D bioprinting.

How they like to work

OZ Biosciences consistently joins projects as a participant or third party — never as coordinator — which is typical of a specialist SME that contributes a defined technical capability rather than managing large consortia. With 47 unique partners across 12 countries from just 4 projects, they operate in mid-to-large consortia and appear comfortable integrating into diverse international teams. Their role pattern suggests they are sought out for what they bring to the table (delivery formulations, testing capabilities) rather than for project management.

Despite only 4 projects, OZ Biosciences has built a broad network of 47 partners across 12 countries, reflecting their participation in large MSCA training networks and multi-partner RIA consortia. Their network spans Western and Southern Europe with strong academic and clinical research connections.

What sets them apart

OZ Biosciences occupies a niche that few SMEs fill: they bridge the gap between molecular delivery science and applied regenerative medicine, providing the formulation know-how that turns a lab-stage gene therapy concept into a deliverable therapeutic product. Their combination of transfection/delivery reagent expertise with hands-on experience in 3D-printed bone implant development makes them a practical partner for any consortium that needs to get biological agents reliably into tissues. For a consortium builder, they offer a commercially minded SME that already has products on the market in the delivery space, reducing the risk of working with a purely academic partner.

Highlights from their portfolio

• SBR
  Largest single EC contribution (EUR 480,500) and most technically ambitious — combines smart sensors, wireless monitoring, and bioactive 3D-printed implants for bone regeneration.
• cmRNAbone
  Sits at the frontier of gene therapy and 3D bioprinting, developing chemically modified RNA-loaded printed matrices for bone repair — a highly translational approach with regulatory pathway considerations built in.